Like humans, dogs can experience cognitive decline as they get older. This is called canine cognitive dysfunction (CCD). Studies from the Behavior Clinic at the University of California at Davis have found that 27% of dogs aged 11-12 have CCD. That number jumps to 68% for dogs aged 15-16. However, a new study shows there may be some promise for treatment.
The drug in question is called Ropesalazine. Researchers examined a group of companion dogs who were diagnosed with CCD after being rated on canine cognitive dysfunction scales. After eight weeks of being on the medication, the dogs were re-examined. This time, all the dogs had returned to a normal range of cognitive function and daily activity.
These results were in keeping with previous studies that examined Ropesalazine in mice. The drug is also being considered for treating humans with dementia.
The next step is for researchers to move towards clinical studies for the medication.
McReynolds, Tony. “New Drug Shows Hope for Treatment of Dog Dementia.” American Animal Hospital Association, www.aaha.org/blog/NewStat/post/2018/09/05/429076/New-drug-shows-hope-for-treatment-of-dog-dementia.aspx.